
StatSure Diagnostic Systems Inc. Stock Analysis SSUR
StatSure Diagnostic Systems, Inc. engages in the research, development, and market of diagnostic tests for the detection of Human Immunodeficiency Virus. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The Company’s StatSure Diagnostic Systems, Inc.’s SURE CHECK HIV 1/ 2 and Clearview Complete HIV 1/ 2 tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2. The Company’s HIV 1/ 2 diagnostic test is manufactured in the United States by Chembio Diagnostics is sold in the United States to clinics, hospitals and physicians by Alere under the brand name Complete HIV 1/ 2. Since the Company has introduced HIV rapid test product, its annual sales have shown very rapid growth. The Company’s Barrel Test format which is easy to use, needs only 2.5ml of blood (a fingerprick) and is designed specifically for consumers will become the consumer test of choice.
Read More StatSure Diagnostic Systems Inc (SSUR) Chart
Key Statistics of StatSure Diagnostic Systems Inc (SSUR)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
180.00P/E Ratio (TTM)
-Market Cap
10.00KAvg. Volume
180.00Dividend Yield
-Financial Metrics & Statements of StatSure Diagnostic Systems Inc (SSUR)
FAQ's for StatSure Diagnostic Systems Inc (SSUR)
- According to Musaffa’s Shariah screening methodology, StatSure Diagnostic Systems Inc (SSUR) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.